407 related articles for article (PubMed ID: 26364321)
1. Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.
Shiroishi MS; Boxerman JL; Pope WB
Neuro Oncol; 2016 Apr; 18(4):467-78. PubMed ID: 26364321
[TBL] [Abstract][Full Text] [Related]
2. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
[TBL] [Abstract][Full Text] [Related]
3. Dynamic Susceptibility Contrast MR Imaging in Glioma: Review of Current Clinical Practice.
Boxerman JL; Shiroishi MS; Ellingson BM; Pope WB
Magn Reson Imaging Clin N Am; 2016 Nov; 24(4):649-670. PubMed ID: 27742108
[TBL] [Abstract][Full Text] [Related]
4. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
[TBL] [Abstract][Full Text] [Related]
5. Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma.
Tensaouti F; Khalifa J; Lusque A; Plas B; Lotterie JA; Berry I; Laprie A; Cohen-Jonathan Moyal E; Lubrano V
Neuroradiology; 2017 Oct; 59(10):1013-1020. PubMed ID: 28842741
[TBL] [Abstract][Full Text] [Related]
6. Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis.
Delgado-López PD; Riñones-Mena E; Corrales-García EM
Clin Transl Oncol; 2018 Aug; 20(8):939-953. PubMed ID: 29218626
[TBL] [Abstract][Full Text] [Related]
7. Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.
Chu HH; Choi SH; Ryoo I; Kim SC; Yeom JA; Shin H; Jung SC; Lee AL; Yoon TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
Radiology; 2013 Dec; 269(3):831-40. PubMed ID: 23771912
[TBL] [Abstract][Full Text] [Related]
8. Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review. Part 2 - Radiological features and metric markers.
Le Fèvre C; Constans JM; Chambrelant I; Antoni D; Bund C; Leroy-Freschini B; Schott R; Cebula H; Noël G
Crit Rev Oncol Hematol; 2021 Mar; 159():103230. PubMed ID: 33515701
[TBL] [Abstract][Full Text] [Related]
9. Metabolic and physiologic magnetic resonance imaging in distinguishing true progression from pseudoprogression in patients with glioblastoma.
Chawla S; Bukhari S; Afridi OM; Wang S; Yadav SK; Akbari H; Verma G; Nath K; Haris M; Bagley S; Davatzikos C; Loevner LA; Mohan S
NMR Biomed; 2022 Jul; 35(7):e4719. PubMed ID: 35233862
[TBL] [Abstract][Full Text] [Related]
10. Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.
Strauss SB; Meng A; Ebani EJ; Chiang GC
Neuroimaging Clin N Am; 2021 Feb; 31(1):103-120. PubMed ID: 33220823
[TBL] [Abstract][Full Text] [Related]
11. Differentiation of Pseudoprogression from True Progressionin Glioblastoma Patients after Standard Treatment: A Machine Learning Strategy Combinedwith Radiomics Features from T
Sun YZ; Yan LF; Han Y; Nan HY; Xiao G; Tian Q; Pu WH; Li ZY; Wei XC; Wang W; Cui GB
BMC Med Imaging; 2021 Feb; 21(1):17. PubMed ID: 33535988
[TBL] [Abstract][Full Text] [Related]
12. Response Assessment and Magnetic Resonance Imaging Issues for Clinical Trials Involving High-Grade Gliomas.
Boxerman JL; Ellingson BM
Top Magn Reson Imaging; 2015 Jun; 24(3):127-36. PubMed ID: 26049816
[TBL] [Abstract][Full Text] [Related]
13. Differentiating Tumor Progression from Pseudoprogression in Patients with Glioblastomas Using Diffusion Tensor Imaging and Dynamic Susceptibility Contrast MRI.
Wang S; Martinez-Lage M; Sakai Y; Chawla S; Kim SG; Alonso-Basanta M; Lustig RA; Brem S; Mohan S; Wolf RL; Desai A; Poptani H
AJNR Am J Neuroradiol; 2016 Jan; 37(1):28-36. PubMed ID: 26450533
[TBL] [Abstract][Full Text] [Related]
14. Imaging of the Posttherapeutic Brain.
Telles BA; D'Amore F; Lerner A; Law M; Shiroishi MS
Top Magn Reson Imaging; 2015 Jun; 24(3):147-54. PubMed ID: 26049818
[TBL] [Abstract][Full Text] [Related]
15. Visual inspection of MR relative cerebral blood volume maps has limited value for distinguishing progression from pseudoprogression in glioblastoma multiforme patients.
Kerkhof M; Tans PL; Hagenbeek RE; Lycklama À Nijeholt GJ; Holla FK; Postma TJ; Straathof CS; Dirven L; Taphoorn MJ; Vos MJ
CNS Oncol; 2017 Oct; 6(4):297-306. PubMed ID: 28984142
[TBL] [Abstract][Full Text] [Related]
16. Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas.
Lee WJ; Choi SH; Park CK; Yi KS; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH
Acad Radiol; 2012 Nov; 19(11):1353-61. PubMed ID: 22884399
[TBL] [Abstract][Full Text] [Related]
17. Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.
Strauss SB; Meng A; Ebani EJ; Chiang GC
Radiol Clin North Am; 2019 Nov; 57(6):1199-1216. PubMed ID: 31582045
[TBL] [Abstract][Full Text] [Related]
18. Differentiation of progressive disease from pseudoprogression using MRI histogram analysis in patients with treated glioblastoma.
Yildirim M; Baykara M
Acta Neurol Belg; 2022 Apr; 122(2):363-368. PubMed ID: 33555560
[TBL] [Abstract][Full Text] [Related]
19. Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma.
Li Y; Ma Y; Wu Z; Xie R; Zeng F; Cai H; Lui S; Song B; Chen L; Wu M
Front Immunol; 2021; 12():790674. PubMed ID: 34899760
[TBL] [Abstract][Full Text] [Related]
20. Recent Application of Advanced MR Imaging to Predict Pseudoprogression in High-grade Glioma Patients.
Yoo RE; Choi SH
Magn Reson Med Sci; 2016; 15(2):165-77. PubMed ID: 26726012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
